Stay up-to-date with the latest developments in securities law through access to both news and all statutes and regulations. Find relevant corporate filings through a searchable EDGAR database. And...
Valeant Pharmaceuticals faces a BlackRock Inc. lawsuit alleging the company misled it and other investors about illegal ties to a mail-order pharmacy that led to a massive drop in stock prices.
BlackRock said it suffered a 90 percent drop in the price of its Valeant shares when an alleged kickback scheme between Valeant Pharmaceuticals International Inc. and Philidor Rx Services executives was uncovered.
BlackRock brought the lawsuit on behalf of over 80 investment funds it manages or advises in the U.S. District Court for the District of New Jersey.
According to the Jan. 9 complaint, Valeant concealed critical information from BlackRock and other investors about its relationship with Philidor. The alleged relationship included Valeant employees working at Philidor and engaging in “deceptive practices” such as refusing to substitute generics for Valeant drugs, the complaint said.
U.S. prosecutors have indicted Gary Tanner, a former senior director at Valeant, and Andrew Davenport, the former CEO of Philidor, over the alleged fraud. Tanner is accused of driving business and funding from Valeant to Philidor in return for millions of dollars in kickbacks. The pair February 2017 pleaded not guilty in the U.S. District Court for the Southern District of New York.
Valeant also faces several other shareholder suits based on the alleged scheme. Valeant representatives didn’t immediately respond to requests for comment.
According to BlackRock’s complaint, the fraudulent practices artificially boosted Valeant’s revenues and stock prices. Valeant stock lost almost all its value when the Philidor connection and other “rampant misconduct” became public, leading to large investor losses, it said.
Valeant also billed itself as using a “lower risk, output-focused research and development model,” according to the complaint. Instead, Valeant’s allegedly shady practices opened the company up to more costly investigations, sanctions, and criminal charges, it said.
The case is BlackRock Glob. Allocation Fund Inc. v. Valeant Pharm. Int’l Inc. , D.N.J., No. 3:18-cv-00343, 1/9/18 .
To contact the reporter on this story: Jennifer Bennett in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Seth Stern at email@example.com
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)